
The board of the Kansas City Southern railroad is reconsidering a $27bn offer from Canadian Pacific, despite an agreement to sell the company to a rival, after a US regulator rejected how the earlier deal was structured, reported The Financial Times.
The board of the railroad, which is headquartered in Kansas City, Missouri and runs between that city and Mexico, said on Saturday that Canadian Pacific’s offer “could reasonably be expected to lead to” a “superior” offer than the one Canadian National made in May to buy the railroad for $30bn. Kansas City Southern said it would open its books to Canadian Pacific, but that the move would not necessarily lead to a deal.
Both Canadian railroads are pursuing the rare opportunity to extend their reach into the US by snapping up one of only seven large railroads in North America. Canadian Pacific has previously said that its competitor’s larger offer nods to the greater regulatory scrutiny the deal faces.
If Canadian National acquires Kansas City Southern, the railroad would be the third largest on the continent. A tie-up with Canadian Pacific would still be the smallest of the six remaining big rail operators.
Last week the US Surface Transportation Board, which regulates railroads, ruled that a “voting trust” proposed by Canadian National could not be used. The trust would have allowed shareholders of Kansas City Southern to receive payment before the merger was approved.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas